Abstract 609P
Background
Pembrolizumab, a checkpoint inhibitor, has revolutionized the treatment of advanced melanoma by harnessing the immune system to target cancer cells. However, its use is associated with immune-related adverse events, including vitiligo and thyroid function abnormalities. This study aims to investigate the association between thyroid function abnormalities and vitiligo induced by pembrolizumab, specifically focusing on the prognosis in patients with advanced melanoma.
Methods
A retrospective survey of medical records and treatment outcomes of patients with locally advanced/metastatic melanoma receiving pembrolizumab was conducted. The study reported data on the incidence of vitiligo, thyroid function abnormalities, and their impact on prognosis. Data was collected from multiple oncology centers across Iraq. Kaplan-Meier survival curves and Cox regression were used for statistical analysis.
Results
One hundred cases with advanced melanoma were included in this study. The mean age of the samples was 55.8 ± 15.5 years old. Male to female ratio was 0.79. The Incidence of vitiligo was reported to be 27%, mainly in the survived-group (35.2%, P-value = 0.046). It took an average of 12 weeks for the development of vitiligo. The incidence of thyroid dysfunction was found to be 22%. The development of vitiligo significantly improved survival in patients with advanced melanoma (log-rank test = 0.043). On the other hand, the occurrence of thyroid dysfunction as an immune-side effect to treatment did not have an effect on the overall survival of the cohort.
Conclusions
The findings of this study suggest that there is an association between the incidence of vitiligo induced by pembrolizumab and overall survival in patients with advanced melanoma. However, no such relationship was found in regard to the development of thyroid dysfunction.
Clinical trial identification
Editorial acknowledgement
Dr. Ahmed Z. Al-Samaraee, Medical oncologist, Oncology teaching hospital, Baghdad Dr Maha S. Sahib, Clinical Pharmacist, Baghdad Dr Ayad R Alasadi, Medical oncologist, Al-Amal Hospital, Baghdad.
Legal entity responsible for the study
Oncology Teaching Hospital, Medical City Complex, Baghdad.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract